Food and Drug Administration (FDA)-approved semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro)
If your insurance does not approve medications like Wegovy or Zepbound, compounded semaglutide or tirzepatide may be an alternative
NICE guidance emphasises individualised care, and treatment decisions should be made collaboratively between patients and healthcare professionals, considering the overall benefit-risk profile for each individual
As body weight decreases, the dose of levothyroxine needed to maintain euthyroidism may change, typically requiring a reduction in thyroid hormone replacement
Abstract While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to increase heart rate (HR), it is insufficiently recognized that the extent varies greatly between the various agonists and is affected by the assessment methods employed
Mechanisms of Weight Loss (The Brain and Gut) GLP-1 RAs promote weight loss through a gut-brain axis, acting on receptors in the CNS and gastrointestinal tract to regulate energy balance (Zheng et al., 2024)
